MeSH term
Frequency | Condition_Probility | Animals | 20 | 0.0 |
Humans | 586 | 0.0 |
Child, Preschool | 32 | 0.0 |
United States/epidemiology | 4 | 1.0 |
Adult | 286 | 0.0 |
Child | 40 | 0.0 |
*Disease Transmission, Vertical | 2 | 2.0 |
Fatal Outcome | 2 | 0.0 |
Female | 387 | 0.0 |
Influenza/*transmission/virology | 2 | 25.0 |
Influenza A Virus, Avian/*genetics/isolation & purification | 2 | 25.0 |
Influenza, Avian/transmission | 2 | 25.0 |
Lung/radiography | 2 | 7.0 |
Phylogeny | 2 | 0.0 |
Poultry | 2 | 12.0 |
Research Support, Non-U.S. Gov't | 387 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 13 | 0.0 |
Zoonoses/transmission | 2 | 25.0 |
Aged | 180 | 0.0 |
Genotype | 339 | 3.0 |
Male | 383 | 0.0 |
Middle Aged | 320 | 0.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Proportional Hazards Models | 5 | 0.0 |
Survival Rate | 9 | 0.0 |
Australia | 3 | 1.0 |
Carcinoma, Squamous Cell/epidemiology/genetics | 3 | 60.0 |
Glutathione Transferase/*genetics | 317 | 47.0 |
*Polymorphism, Genetic | 209 | 4.0 |
Risk Factors | 165 | 2.0 |
Smoking/adverse effects | 32 | 11.0 |
Ultraviolet Rays/adverse effects | 3 | 4.0 |
*Gene Deletion | 18 | 2.0 |
Glucocorticoids/*therapeutic use | 2 | 5.0 |
Infant | 19 | 0.0 |
Infant, Newborn | 16 | 0.0 |
Aged, 80 and over | 65 | 0.0 |
Arylsulfotransferase/genetics | 2 | 40.0 |
Case-Control Studies | 193 | 3.0 |
Catechol O-Methyltransferase/genetics | 3 | 10.0 |
Comparative Study | 80 | 0.0 |
DNA/genetics | 8 | 0.0 |
DNA Repair | 5 | 0.0 |
*Genetic Predisposition to Disease | 73 | 6.0 |
Glutathione Transferase/genetics | 74 | 25.0 |
Superoxide Dismutase/genetics | 3 | 3.0 |
Taiwan/epidemiology | 10 | 8.0 |
Tumor Markers, Biological/*genetics | 3 | 2.0 |
Cells, Cultured | 20 | 0.0 |
Comet Assay | 7 | 10.0 |
Cytochrome P-450 CYP2E1/genetics | 17 | 44.0 |
Environmental Monitoring/methods | 2 | 15.0 |
Italy | 4 | 0.0 |
Lymphocytes/*drug effects | 5 | 12.0 |
Mutagens/*adverse effects | 2 | 33.0 |
Occupational Exposure/analysis | 2 | 40.0 |
Polymorphism, Genetic | 137 | 3.0 |
Questionnaires | 11 | 2.0 |
Sister Chromatid Exchange | 8 | 16.0 |
Smoking | 34 | 8.0 |
Amino Acid Substitution | 4 | 0.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 2 | 1.0 |
Substrate Specificity | 5 | 0.0 |
Adolescent | 61 | 0.0 |
Follow-Up Studies | 11 | 0.0 |
Gene Frequency | 59 | 1.0 |
Isoenzymes/genetics | 40 | 12.0 |
Prognosis | 22 | 0.0 |
Analysis of Variance | 11 | 0.0 |
Polymorphism, Genetic/genetics | 14 | 2.0 |
Statistics, Nonparametric | 5 | 0.0 |
DNA/blood | 4 | 2.0 |
DNA Repair/*genetics | 4 | 1.0 |
European Continental Ancestry Group | 8 | 1.0 |
Mutagens/*pharmacology | 3 | 10.0 |
Risk | 21 | 2.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Base Sequence | 33 | 0.0 |
DNA Primers | 29 | 0.0 |
Ethnic Groups/genetics | 3 | 1.0 |
Isoenzymes/*genetics | 51 | 11.0 |
Neoplasm Metastasis | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 108 | 0.0 |
Retrospective Studies | 7 | 0.0 |
Survival Analysis | 9 | 0.0 |
Time Factors | 16 | 0.0 |
Genetic Predisposition to Disease/*genetics | 7 | 1.0 |
*Genotype | 9 | 4.0 |
Leukemia, Lymphocytic, Acute, L1/enzymology/epidemiology/*genetics | 2 | 100.0 |
Treatment Outcome | 13 | 0.0 |
Tumor Markers, Biological/genetics | 5 | 5.0 |
Dose-Response Relationship, Drug | 8 | 0.0 |
In Vitro | 7 | 0.0 |
Carcinoma, Squamous Cell/*genetics/mortality/pathology | 2 | 14.0 |
Cytochrome P-450 Enzyme System/*genetics | 18 | 4.0 |
DNA Mutational Analysis | 6 | 0.0 |
Disease-Free Survival | 9 | 0.0 |
English Abstract | 22 | 0.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Neoplasm Staging | 7 | 0.0 |
Polymorphism, Genetic/*genetics | 33 | 2.0 |
*Environmental Exposure | 4 | 5.0 |
Odds Ratio | 61 | 5.0 |
Pregnancy | 12 | 0.0 |
*Prenatal Exposure Delayed Effects | 2 | 4.0 |
Risk Assessment | 25 | 3.0 |
*Chromosome Aberrations | 12 | 2.0 |
*DNA Primers | 2 | 7.0 |
*Sister Chromatid Exchange | 12 | 37.0 |
Xenobiotics/*metabolism | 5 | 9.0 |
Occupational Exposure/*adverse effects | 19 | 20.0 |
Oxidoreductases/*genetics | 2 | 2.0 |
Paint/adverse effects | 2 | 100.0 |
Solvents/*adverse effects | 5 | 55.0 |
Blotting, Western | 2 | 0.0 |
*Carcinogens | 2 | 6.0 |
Enzyme-Linked Immunosorbent Assay | 5 | 0.0 |
Occupational Exposure | 10 | 12.0 |
Protein p53/*biosynthesis | 2 | 1.0 |
Cytochrome P-450 CYP1A1/*genetics | 32 | 17.0 |
*DNA Adducts | 2 | 5.0 |
Lymphocytes/drug effects | 6 | 8.0 |
Cytochrome P-450 CYP1A1/genetics | 30 | 31.0 |
Enzymes/*genetics/metabolism | 5 | 55.0 |
Homozygote | 30 | 1.0 |
Metabolic Detoxication, Drug | 5 | 6.0 |
Mutation | 21 | 0.0 |
Xenobiotics/metabolism | 11 | 25.0 |
Lymphocytes/*drug effects/enzymology | 2 | 18.0 |
Styrene/*toxicity | 3 | 42.0 |
India | 8 | 2.0 |
Tobacco | 3 | 10.0 |
Age Factors | 17 | 0.0 |
Alcohol Drinking | 4 | 3.0 |
Aldehyde Dehydrogenase/genetics | 4 | 13.0 |
Carcinogens/*adverse effects | 5 | 22.0 |
Cohort Studies | 23 | 0.0 |
Cytochrome P-450 CYP2E1/*genetics | 15 | 12.0 |
DNA-Binding Proteins/*genetics | 7 | 0.0 |
Prevalence | 8 | 0.0 |
Vinyl Chloride/*adverse effects | 2 | 40.0 |
DNA-Formamidopyrimidine Glycosylase | 2 | 3.0 |
Polymerase Chain Reaction | 120 | 1.0 |
Predictive Value of Tests | 3 | 0.0 |
Superoxide Dismutase/*genetics | 2 | 1.0 |
Biotransformation | 9 | 1.0 |
Carcinogens/metabolism | 7 | 21.0 |
Cytochrome P-450 CYP2D6/*genetics | 12 | 20.0 |
India/ethnology | 3 | 4.0 |
Acyltransferases/*genetics | 10 | 23.0 |
DNA, Neoplasm | 2 | 1.0 |
Sex Factors | 16 | 1.0 |
DNA Adducts/*analysis | 4 | 9.0 |
DNA, Neoplasm/analysis | 4 | 0.0 |
NAD(P)H Dehydrogenase (Quinone)/*genetics | 6 | 8.0 |
Glutathione Transferase/*genetics/metabolism | 33 | 43.0 |
Industry | 3 | 9.0 |
Lymphocytes | 3 | 1.0 |
Micronuclei, Chromosome-Defective | 2 | 18.0 |
*Occupational Exposure | 30 | 21.0 |
Shoes | 2 | 33.0 |
Sister Chromatid Exchange/*drug effects | 6 | 20.0 |
Glucuronates/*urine | 2 | 50.0 |
Isoenzymes | 5 | 2.0 |
Mutagens/*analysis | 4 | 23.0 |
Polycyclic Hydrocarbons, Aromatic/*adverse effects | 3 | 27.0 |
Pyrenes | 3 | 50.0 |
DNA Damage | 7 | 0.0 |
Arylamine N-Acetyltransferase/*genetics/metabolism | 4 | 7.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 5 | 4.0 |
DNA Damage/*genetics | 4 | 6.0 |
Leukocytes | 2 | 3.0 |
Acetylation | 3 | 0.0 |
Genetic Predisposition to Disease | 73 | 3.0 |
Isoenzymes/*genetics/metabolism | 4 | 6.0 |
Acute Disease | 8 | 0.0 |
Alleles | 50 | 0.0 |
Acetyltransferases/*genetics | 5 | 9.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 5 | 1.0 |
Disease Susceptibility | 17 | 2.0 |
Biological Markers/urine | 3 | 4.0 |
Deoxyguanosine/*analogs & derivatives/urine | 2 | 33.0 |
Oxidative Stress/*genetics | 4 | 15.0 |
Peroxidase/genetics | 4 | 30.0 |
Polymorphism, Restriction Fragment Length | 35 | 1.0 |
*Environment | 2 | 4.0 |
Gene Expression Profiling | 3 | 0.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Glutathione Transferase/biosynthesis/genetics | 3 | 21.0 |
Lung Neoplasms/enzymology/*genetics | 5 | 13.0 |
Multivariate Analysis | 15 | 1.0 |
Oxidation-Reduction | 2 | 0.0 |
Longitudinal Studies | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 20 | 0.0 |
Benzene/*adverse effects | 5 | 83.0 |
Environmental Exposure/*adverse effects | 2 | 7.0 |
Genetics, Population | 4 | 1.0 |
Point Mutation | 3 | 0.0 |
Cotinine/urine | 2 | 28.0 |
DNA Adducts | 6 | 8.0 |
*DNA Damage | 13 | 2.0 |
Exons | 8 | 0.0 |
Asthma/enzymology/etiology/*genetics | 2 | 100.0 |
Smoking/*adverse effects | 29 | 13.0 |
Glutathione Transferase/*genetics/*metabolism | 3 | 23.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 5 | 1.0 |
Gene Deletion | 18 | 0.0 |
Remission Induction | 2 | 0.0 |
Smoking/epidemiology | 5 | 7.0 |
Inhalation Exposure | 2 | 9.0 |
Korea | 9 | 4.0 |
Regression Analysis | 18 | 1.0 |
Statistics | 2 | 0.0 |
Acyltransferases/genetics | 5 | 31.0 |
Balkan Nephropathy/*genetics | 2 | 100.0 |
Genetic Heterogeneity | 2 | 0.0 |
*Gene Frequency | 4 | 0.0 |
Chromosome Aberrations | 9 | 1.0 |
Karyotyping | 5 | 0.0 |
Lymphocytes/enzymology | 3 | 3.0 |
Translocation, Genetic | 2 | 0.0 |
Linear Models | 7 | 1.0 |
Logistic Models | 24 | 3.0 |
Breast Neoplasms/etiology/*genetics | 3 | 9.0 |
Catechol O-Methyltransferase/*genetics | 3 | 3.0 |
Arylamine N-Acetyltransferase/*genetics | 15 | 7.0 |
Germ-Line Mutation | 2 | 0.0 |
Acetylcysteine/*analogs & derivatives/*urine | 2 | 100.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
European Continental Ancestry Group/genetics | 7 | 1.0 |
Italy/epidemiology | 4 | 1.0 |
Occupational Exposure/*statistics & numerical data | 3 | 60.0 |
Quinone Reductases/genetics | 4 | 57.0 |
Seasons | 4 | 2.0 |
Sorbic Acid/*analogs & derivatives/*metabolism | 2 | 100.0 |
Workplace | 2 | 40.0 |
Carcinogens/*toxicity | 3 | 2.0 |
Chemical Industry | 3 | 25.0 |
China | 12 | 2.0 |
Tumor Markers, Biological | 5 | 1.0 |
Bladder Neoplasms/epidemiology/*genetics | 3 | 37.0 |
Asbestos/*adverse effects | 2 | 14.0 |
Databases, Factual | 3 | 1.0 |
African Continental Ancestry Group/*genetics | 4 | 1.0 |
Cytochrome P-450 Enzyme System/genetics | 6 | 5.0 |
European Continental Ancestry Group/*genetics | 4 | 1.0 |
Linkage (Genetics) | 2 | 0.0 |
Neoplasms/*genetics | 4 | 1.0 |
Adenocarcinoma/enzymology/*genetics/pathology | 2 | 33.0 |
Codon | 5 | 1.0 |
Genes, p53/*genetics | 9 | 2.0 |
Genetic Predisposition to Disease/genetics | 13 | 3.0 |
Lung Neoplasms/enzymology/*genetics/pathology | 2 | 25.0 |
Cell Line | 2 | 0.0 |
Glutathione Transferase/genetics/metabolism | 9 | 7.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
*Diet | 10 | 4.0 |
*Fruit | 3 | 27.0 |
Glutathione Transferase/*genetics/pharmacology | 8 | 72.0 |
Great Britain | 3 | 1.0 |
Phenotype | 21 | 0.0 |
*Vegetables | 5 | 38.0 |
Chromosome Aberrations/chemically induced | 2 | 33.0 |
*Cocarcinogenesis | 3 | 14.0 |
Pilot Projects | 5 | 0.0 |
Cytochrome P-450 CYP1A1/chemistry/*genetics | 4 | 57.0 |
Endometriosis/enzymology/*genetics | 3 | 50.0 |
Glutathione Transferase/chemistry/*genetics | 6 | 50.0 |
Pedigree | 2 | 0.0 |
Epidemiologic Studies | 4 | 8.0 |
Population Surveillance | 3 | 1.0 |
Xenobiotics/*adverse effects | 2 | 66.0 |
Metabolic Detoxication, Drug/genetics | 2 | 10.0 |
Sister Chromatid Exchange/*genetics | 2 | 33.0 |
Breast Neoplasms/*genetics | 3 | 0.0 |
Smoking/epidemiology/genetics | 3 | 75.0 |
Glutathione Transferase/*analysis/metabolism | 2 | 100.0 |
Endometriosis/*genetics | 2 | 11.0 |
*Linkage (Genetics) | 3 | 0.0 |
Breast Neoplasms/*epidemiology/*genetics | 2 | 5.0 |
Chromosome Deletion | 2 | 0.0 |
Heterozygote Detection | 3 | 0.0 |
Cytochrome P-450 CYP1A1/genetics/metabolism | 3 | 10.0 |
Environmental Monitoring | 3 | 7.0 |
Naphthols/*urine | 2 | 40.0 |
Pyrenes/*analysis | 3 | 50.0 |
Metallurgy | 3 | 23.0 |
Smoking/urine | 2 | 40.0 |
Biological Markers/analysis | 4 | 0.0 |
Epoxide Hydrolases/genetics/*metabolism | 2 | 40.0 |
Glutathione Transferase/genetics/*metabolism | 3 | 21.0 |
Xenobiotics | 2 | 28.0 |
Epoxide Hydrolases/genetics | 6 | 46.0 |
Glutathione Transferase/metabolism | 3 | 0.0 |
Lung Neoplasms/*genetics | 9 | 3.0 |
Arylamine N-Acetyltransferase/genetics | 15 | 25.0 |
Hepatitis B Surface Antigens/blood | 2 | 7.0 |
Seroepidemiologic Studies | 2 | 1.0 |
DNA, Neoplasm/genetics | 10 | 1.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
Mouth Neoplasms/*genetics | 2 | 4.0 |
Neoplasm Proteins/*genetics | 6 | 0.0 |
Polymerase Chain Reaction/methods | 6 | 0.0 |
Chronic Disease | 6 | 0.0 |
*Polymorphism, Genetic/*genetics | 2 | 33.0 |
Oxidative Stress/genetics | 3 | 12.0 |
Reference Values | 14 | 0.0 |
Heterozygote | 9 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Smoking/genetics | 3 | 15.0 |
Biological Markers | 10 | 0.0 |
Styrene/*adverse effects/metabolism | 2 | 100.0 |
Glutathione/blood | 4 | 9.0 |
Oxidative Stress | 5 | 1.0 |
Asthma/*genetics | 4 | 6.0 |
Carcinoma, Basal Cell/*genetics | 3 | 21.0 |
Skin Neoplasms/*genetics | 3 | 2.0 |
DNA Adducts/blood | 2 | 25.0 |
Diet | 5 | 1.0 |
Glutathione Transferase/*deficiency/genetics | 2 | 33.0 |
China/epidemiology | 8 | 4.0 |
Data Collection | 2 | 2.0 |
Epidemiology, Molecular | 4 | 4.0 |
Carcinoma, Squamous Cell/epidemiology/*genetics | 6 | 35.0 |
*Kidney Transplantation | 2 | 0.0 |
*Arylamine N-Acetyltransferase | 2 | 18.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Loss of Heterozygosity | 2 | 0.0 |
*Mutation | 6 | 0.0 |
Polymorphism, Single-Stranded Conformational | 6 | 0.0 |
Proteins/*genetics | 3 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 3 | 6.0 |
Netherlands/epidemiology | 3 | 2.0 |
Colorectal Neoplasms/*epidemiology/*genetics | 2 | 40.0 |
Glutathione Transferase/*blood | 4 | 66.0 |
Protein p53/genetics | 2 | 1.0 |
Asia/epidemiology | 3 | 18.0 |
*Genetics, Population | 2 | 0.0 |
Incidence | 12 | 0.0 |
Lung Neoplasms/enzymology/*etiology/genetics | 3 | 50.0 |
DNA Adducts/*metabolism | 8 | 17.0 |
Mass Fragmentography | 2 | 0.0 |
Smoking/*metabolism | 2 | 4.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
Colorectal Neoplasms/*enzymology/genetics | 2 | 28.0 |
Cross-Sectional Studies | 11 | 0.0 |
*DNA Repair | 4 | 0.0 |
Guanine/analogs & derivatives/*metabolism | 2 | 50.0 |
*Chromosome Deletion | 4 | 0.0 |
Europe/epidemiology | 3 | 3.0 |
Gene Frequency/genetics | 6 | 1.0 |
Head and Neck Neoplasms/epidemiology/*genetics | 2 | 40.0 |
Variation (Genetics)/genetics | 2 | 1.0 |
Administration, Inhalation | 2 | 1.0 |
Monte Carlo Method | 2 | 2.0 |
Epoxide Hydrolases/*genetics/metabolism | 2 | 28.0 |
Age of Onset | 9 | 0.0 |
DNA Primers/genetics | 3 | 0.0 |
Glutathione Transferase/deficiency/*genetics | 8 | 88.0 |
Isoenzymes/deficiency/*genetics | 2 | 33.0 |
Sequence Deletion | 2 | 0.0 |
Acetyltransferases/genetics | 6 | 16.0 |
Apolipoproteins E/genetics | 2 | 0.0 |
Cytochrome P-450 CYP2D6/genetics | 10 | 32.0 |
Adenocarcinoma/*enzymology/genetics | 2 | 16.0 |
Epoxide Hydrolases/*genetics | 12 | 37.0 |
Feasibility Studies | 2 | 0.0 |
Sensitivity and Specificity | 16 | 0.0 |
*Alleles | 4 | 0.0 |
*Aryl Hydrocarbon Hydroxylases | 2 | 0.0 |
Carcinoma, Squamous Cell/enzymology/*genetics | 4 | 25.0 |
Smoking/adverse effects/genetics | 3 | 30.0 |
DNA Adducts/*genetics | 3 | 42.0 |
Ethylene Oxide/*adverse effects | 3 | 100.0 |
Glutathione Transferase/analysis/*genetics | 3 | 42.0 |
Probability | 6 | 0.0 |
Sister Chromatid Exchange/*drug effects/genetics | 2 | 66.0 |
Confidence Intervals | 13 | 3.0 |
Molecular Sequence Data | 15 | 0.0 |
England | 3 | 2.0 |
Carcinoma, Basal Cell/enzymology/*genetics | 4 | 80.0 |
Skin Neoplasms/enzymology/*genetics | 4 | 50.0 |
Tumor Necrosis Factor-alpha/genetics | 3 | 1.0 |
Variation (Genetics) | 3 | 0.0 |
Syndrome | 2 | 0.0 |
DNA, Neoplasm/*genetics | 5 | 2.0 |
Prospective Studies | 9 | 0.0 |
Disease Progression | 4 | 0.0 |
Genes, bcl-2/genetics | 2 | 5.0 |
Tumor Necrosis Factor-alpha/*genetics | 2 | 0.0 |
*Life Style | 2 | 3.0 |
Pyrenes/*metabolism | 2 | 14.0 |
Japan | 10 | 0.0 |
Leukemia, Lymphocytic, Acute/*genetics | 2 | 2.0 |
Polymorphism, Genetic/*physiology | 2 | 2.0 |
Age Distribution | 6 | 1.0 |
Genetic Predisposition to Disease/*epidemiology | 3 | 12.0 |
Carcinogens/*metabolism | 4 | 5.0 |
Environmental Exposure | 7 | 4.0 |
France/ethnology | 2 | 5.0 |
Prostatic Neoplasms/*genetics | 2 | 1.0 |
Isoenzymes/genetics/metabolism | 3 | 2.0 |
Cytochrome P-450 CYP1A1/genetics/*metabolism | 2 | 7.0 |
Genetic Markers | 7 | 0.0 |
Cocarcinogenesis | 4 | 15.0 |
Butadienes/*adverse effects | 2 | 66.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 2 | 2.0 |
Microsomes/*enzymology | 3 | 6.0 |
Recurrence | 3 | 0.0 |
Dinitrochlorobenzene/metabolism | 3 | 33.0 |
Tobacco Smoke Pollution/adverse effects | 3 | 33.0 |
Biological Markers/*analysis | 2 | 1.0 |
Mutagenesis/*genetics | 2 | 7.0 |
Cytochrome P-450 CYP1A1/*genetics/metabolism | 3 | 13.0 |
Ovarian Neoplasms/*enzymology/genetics | 2 | 50.0 |
Bladder Neoplasms/*enzymology/epidemiology/*genetics | 2 | 100.0 |
DNA/genetics/isolation & purification | 3 | 1.0 |
Prostatic Neoplasms/*enzymology/epidemiology/*genetics | 2 | 66.0 |
Genetic Predisposition to Disease/epidemiology | 5 | 5.0 |
Neoplasms/epidemiology/*genetics | 2 | 25.0 |
Alcohol Dehydrogenase/genetics | 2 | 8.0 |
Interleukin-1/genetics | 2 | 2.0 |
NAD(P)H Dehydrogenase (Quinone)/genetics | 7 | 41.0 |
Peptidyl-Dipeptidase A/genetics | 2 | 2.0 |
Physical Examination | 2 | 7.0 |
*Smoking | 7 | 8.0 |
Isothiocyanates/*urine | 2 | 66.0 |
Chi-Square Distribution | 10 | 1.0 |
Confounding Factors (Epidemiology) | 3 | 4.0 |
Enzyme Induction | 2 | 0.0 |
Sex Distribution | 3 | 1.0 |
Cyclin D1/*genetics | 2 | 3.0 |
Neoplasms, Multiple Primary/*genetics | 2 | 5.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Reproducibility of Results | 6 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Adenocarcinoma/epidemiology/genetics | 2 | 40.0 |
Biotransformation/genetics | 2 | 22.0 |
Brazil/epidemiology | 5 | 6.0 |
Carcinoma, Large Cell/epidemiology/genetics | 2 | 100.0 |
Carcinoma, Small Cell/epidemiology/genetics | 2 | 66.0 |
Lung Neoplasms/*epidemiology/etiology/*genetics | 2 | 100.0 |
Carcinoma, Squamous Cell/*genetics | 4 | 2.0 |
*Plants, Toxic | 3 | 7.0 |
Quebec/epidemiology | 2 | 6.0 |
Gene Expression | 2 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Polymerase Chain Reaction/*methods | 6 | 1.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
Lung Neoplasms/epidemiology/*genetics | 4 | 28.0 |
Body Mass Index | 2 | 0.0 |
Mixed Function Oxygenases/genetics | 3 | 7.0 |
*Variation (Genetics) | 3 | 0.0 |
Breast Neoplasms/enzymology/*genetics | 2 | 7.0 |
Protein p53/*genetics | 2 | 1.0 |
Prostatic Neoplasms/enzymology/*genetics | 2 | 12.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Glutathione Peroxidase/*genetics | 2 | 8.0 |
Glutathione Transferase/blood/genetics | 2 | 66.0 |
Isoenzymes/blood/genetics | 2 | 11.0 |
Fetal Blood/metabolism | 2 | 3.0 |
Epoxy Compounds/*toxicity | 11 | 55.0 |
Mutagens/*toxicity | 10 | 9.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
Glutathione Transferase/blood/*genetics | 7 | 63.0 |
United States | 3 | 0.0 |
Bone Marrow/pathology | 3 | 0.0 |
Ethylene Oxide/*metabolism | 2 | 100.0 |
Rats | 6 | 0.0 |
*Agriculture | 2 | 20.0 |
Micronucleus Tests | 9 | 18.0 |
Pesticides/*adverse effects | 2 | 15.0 |
Spain | 2 | 0.0 |
Vital Capacity/physiology | 2 | 10.0 |
Deoxyguanosine/analogs & derivatives/analysis | 2 | 50.0 |
Hypoxanthine Phosphoribosyltransferase/*genetics | 2 | 4.0 |
Pharmacogenetics | 3 | 2.0 |
In Situ Hybridization, Fluorescence | 7 | 0.0 |
Mutagenicity Tests | 6 | 3.0 |
Asian Continental Ancestry Group/genetics | 4 | 1.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Japan/epidemiology | 2 | 0.0 |
Butadienes/*toxicity | 2 | 100.0 |
Hemoglobins/metabolism | 3 | 1.0 |
Tobacco Smoke Pollution/*adverse effects | 3 | 9.0 |
Lung Neoplasms/etiology/*genetics | 2 | 7.0 |
India/epidemiology | 3 | 3.0 |
Colorectal Neoplasms/*genetics | 3 | 1.0 |
*DNA Helicases | 2 | 0.0 |
DNA-Binding Proteins/genetics | 3 | 0.0 |
*Transcription Factors | 3 | 0.0 |
Leukemia, Myeloid/enzymology/genetics/physiopathology | 2 | 100.0 |
Myelodysplastic Syndromes/enzymology/*genetics/physiopathology | 2 | 100.0 |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide/metabolism | 2 | 50.0 |
Cytochrome P-450 CYP1A1/biosynthesis/genetics | 2 | 12.0 |
Leukocytes/drug effects/metabolism | 2 | 14.0 |
Leukoplakia/*genetics | 2 | 66.0 |
Lung Neoplasms/etiology/*genetics/metabolism | 2 | 40.0 |
Polycyclic Hydrocarbons, Aromatic/*metabolism | 2 | 11.0 |
Tobacco, Smokeless/*adverse effects | 2 | 25.0 |
Breast Neoplasms/*enzymology/*genetics | 2 | 11.0 |
Plants, Toxic | 2 | 5.0 |
Germany/epidemiology | 2 | 1.0 |
Glutathione Transferase/*genetics/*physiology | 2 | 100.0 |
Neoplasms/*enzymology/*genetics | 2 | 16.0 |
Glutathione Transferase/classification/*genetics | 4 | 80.0 |
DNA Probes | 3 | 0.0 |
Computer Simulation | 2 | 0.0 |
DNA/chemistry/genetics | 4 | 0.0 |
Mice | 4 | 0.0 |
Models, Biological | 2 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Polymorphism, Single Nucleotide/genetics | 2 | 0.0 |
Smoking/*adverse effects/genetics | 4 | 28.0 |
Longevity/*genetics | 2 | 5.0 |
Adenocarcinoma/enzymology/*genetics | 2 | 12.0 |
Aging/*physiology | 2 | 0.0 |
Iran | 4 | 11.0 |
Lung Neoplasms/enzymology/etiology/*genetics | 3 | 75.0 |
Mouth Neoplasms/enzymology/epidemiology/*genetics | 2 | 66.0 |
Electrophoresis | 2 | 0.0 |
DNA/analysis | 4 | 0.0 |
Colorectal Neoplasms/*enzymology/*genetics | 2 | 18.0 |
Carcinoma, Squamous Cell/*epidemiology/*genetics | 2 | 100.0 |
Sweden/epidemiology | 2 | 1.0 |
Lung/*physiopathology | 2 | 10.0 |
Respiratory Function Tests | 3 | 1.0 |
Glutathione Transferase/*metabolism | 4 | 12.0 |
Lipid Peroxidation | 2 | 1.0 |
Turkey | 2 | 1.0 |
Germany | 2 | 0.0 |
Neoplasms/*etiology | 2 | 7.0 |
Sulfotransferases/*genetics | 2 | 5.0 |
Immunohistochemistry | 4 | 0.0 |
Laryngeal Neoplasms/*genetics | 2 | 11.0 |
Carcinoma, Squamous Cell/*enzymology/genetics | 4 | 44.0 |
Lymphocytes/*drug effects/ultrastructure | 2 | 22.0 |
Mutagens/toxicity | 2 | 5.0 |
Amino Acid Sequence | 6 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Lymphocytes/ultrastructure | 2 | 4.0 |
Mutagens | 4 | 12.0 |
Environmental Exposure/adverse effects | 2 | 12.0 |
DNA Damage/*drug effects | 2 | 4.0 |
DNA Repair/*drug effects | 2 | 6.0 |
Chromosome Mapping | 4 | 0.0 |
Cytogenetic Analysis | 2 | 1.0 |
Rats, Inbred F344 | 2 | 0.0 |
Sex Characteristics | 5 | 0.0 |
Cytosol/enzymology | 2 | 1.0 |
China/ethnology | 2 | 1.0 |
Singapore | 2 | 4.0 |
Ovarian Neoplasms/enzymology/*genetics | 2 | 28.0 |
*Oxidative Stress | 4 | 1.0 |
Cloning, Molecular | 3 | 0.0 |
*Multigene Family | 2 | 0.0 |
Haplotypes | 5 | 0.0 |
Myelodysplastic Syndromes/*genetics | 3 | 4.0 |
Epidemiology, Molecular/methods | 2 | 28.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Micronuclei, Chromosome-Defective/drug effects | 2 | 33.0 |
Sister Chromatid Exchange/drug effects | 2 | 10.0 |
Epoxy Compounds/*pharmacology | 3 | 37.0 |
Texas | 2 | 5.0 |
Egypt | 2 | 4.0 |
Postmenopause | 3 | 1.0 |
Premenopause | 2 | 2.0 |
Alcohol Drinking/adverse effects | 3 | 6.0 |
Cytochrome P-450 CYP1A1/blood/*genetics | 2 | 100.0 |
Aryl Hydrocarbon Hydroxylases/genetics | 3 | 12.0 |
France | 2 | 0.0 |
Glutathione Transferase/*genetics/physiology | 3 | 100.0 |
Isoenzymes/*genetics/physiology | 2 | 20.0 |
Smoking/adverse effects/metabolism | 2 | 40.0 |
Texas/epidemiology | 2 | 6.0 |
Smoking/*genetics | 5 | 12.0 |
Sulfotransferases/genetics | 2 | 33.0 |
Breast Neoplasms/*etiology/*genetics | 2 | 22.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
Enzymes/*genetics | 3 | 7.0 |
Pharmaceutical Preparations/*metabolism | 2 | 2.0 |
Adenocarcinoma/genetics | 2 | 2.0 |
Chromosome Aberrations/*genetics | 2 | 1.0 |
*Genes, Structural | 2 | 0.0 |
Cell Division/drug effects | 2 | 0.0 |
Neoplasms/enzymology/epidemiology/*genetics | 2 | 100.0 |
Adenocarcinoma/epidemiology/*genetics | 2 | 20.0 |
Carcinoma, Basal Cell/*epidemiology/genetics | 2 | 100.0 |
Species Specificity | 3 | 0.0 |
Myelodysplastic Syndromes/enzymology/*genetics | 2 | 66.0 |
*Genetic Markers | 5 | 1.0 |
Penetrance | 2 | 1.0 |
*Meat | 2 | 4.0 |
*Gasoline | 2 | 66.0 |
Lung Neoplasms/enzymology/genetics | 2 | 20.0 |
Estonia | 2 | 22.0 |
Lung Neoplasms/*enzymology/etiology/genetics | 2 | 100.0 |
*Genes, p53 | 2 | 0.0 |
Cell Differentiation | 3 | 0.0 |
DNA Primers/chemistry | 4 | 0.0 |
*Chromosomes, Human, Pair 22 | 2 | 0.0 |
Lymphocytes/*drug effects/enzymology/ultrastructure | 2 | 66.0 |
Cytochrome P-450 CYP2D6 | 4 | 5.0 |
Genetic Markers/*genetics | 2 | 1.0 |
Head and Neck Neoplasms/*enzymology/genetics | 2 | 50.0 |
Mixed Function Oxygenases/*genetics | 2 | 1.0 |
Glutathione Transferase/*genetics/*pharmacology | 2 | 100.0 |
Brazil | 3 | 1.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Bladder Neoplasms/*genetics | 2 | 2.0 |
*Tea | 2 | 9.0 |
Portugal/epidemiology | 2 | 11.0 |
Severity of Illness Index | 3 | 0.0 |
Alcohol Drinking/*adverse effects | 5 | 13.0 |
Genetic Screening/methods | 2 | 1.0 |
Leukocyte Count | 2 | 0.0 |
Neoplasms, Second Primary/*genetics | 2 | 9.0 |
Neoplasm Invasiveness | 2 | 0.0 |
*Arylsulfotransferase | 2 | 5.0 |
Prostatic Neoplasms/*enzymology/*genetics/pathology | 2 | 66.0 |
Brassica/*metabolism | 2 | 66.0 |
Esophageal Neoplasms/epidemiology/*genetics | 2 | 25.0 |
*Postmenopause | 2 | 3.0 |
Registries | 2 | 0.0 |
Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 0.0 |
Washington/epidemiology | 2 | 12.0 |
Urinalysis | 2 | 12.0 |
Cytochrome P-450 CYP2E1/*genetics/pharmacology | 2 | 100.0 |
Air Pollutants, Environmental/*adverse effects | 2 | 18.0 |
Arylamine N-Acetyltransferase/genetics/physiology | 2 | 100.0 |
Aryldialkylphosphatase | 2 | 1.0 |
Esterases/genetics | 2 | 11.0 |
